Agenus (AGEN) said Wednesday that the first patient has been enrolled in its phase 3 trial evaluating the immunotherapy combination of botensilimab plus balstilimab against standard care in patients with a type of colorectal cancer.
The company said the trial, led by the Canadian Cancer Trials Group, spans Canada, France, Australia and New Zealand, with more than 100 sites participating.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.